Stern Esther, Pines Guy, Lazar Li Or, Vainer Gilad W, Beltran Nitzan, Dodi Omri, Gamaev Lika, Hikri Simon Ofir, Abraham Michal, Wald Hanna, Peled Amnon, Wald Ori
Gene Therapy Institute, Hadassah Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Department of General Surgery, Kaplan Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Rehovot 76100, Israel.
Biomedicines. 2023 Jan 26;11(2):362. doi: 10.3390/biomedicines11020362.
Given that, even after multimodal therapy, early-stage lung cancer (LC) often recurs, novel prognostic markers to help guide therapy are highly desired. The mRNA levels of cell division cycle 25C (CDC25C), a phosphatase that regulates G2/M cell cycle transition in malignant cells, correlate with poor clinical outcomes in lung adenocarcinoma (LUAD). However, whether CDC25C protein detected by immunohistochemistry can serve as a prognostic marker in LUAD is yet unknown. We stained an LC tissue array and a cohort of 61 LUAD tissue sections for CDC25C and searched for correlations between CDC25C staining score and the pathological characteristics of the tumors and the patients' clinical outcomes. Clinical data were retrieved from our prospectively maintained departmental database. We found that high expression of CDC25C was predominant among poorly differentiated LUAD ( < 0.001) and in LUAD > 1cm ( < 0.05). Further, high expression of CDC25C was associated with reduced disease-free survival ( = 0.03, median follow-up of 39 months) and with a trend for reduced overall survival ( = 0.08). Therefore, high expression of CDC25C protein in LUAD is associated with aggressive histological features and with poor outcomes. Larger studies are required to further validate CDC25C as a prognostic marker in LUAD.
鉴于即使经过多模式治疗，早期肺癌（LC）仍常复发，因此迫切需要有助于指导治疗的新型预后标志物。细胞分裂周期25C（CDC25C）是一种调节恶性细胞中G2/M细胞周期转换的磷酸酶，其mRNA水平与肺腺癌（LUAD）的不良临床结局相关。然而，免疫组织化学检测到的CDC25C蛋白是否可作为LUAD的预后标志物尚不清楚。我们对一个LC组织芯片和一组61例LUAD组织切片进行了CDC25C染色，并寻找CDC25C染色评分与肿瘤病理特征及患者临床结局之间的相关性。临床数据从我们前瞻性维护的科室数据库中检索。我们发现，CDC25C高表达在低分化LUAD中占主导（<0.001），在直径>1cm的LUAD中也占主导（<0.05）。此外，CDC25C高表达与无病生存期缩短相关（=0.03，中位随访39个月），且总生存期有缩短趋势（=0.08）。因此
